<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3806">
  <stage>Registered</stage>
  <submitdate>3/04/2009</submitdate>
  <approvaldate>3/04/2009</approvaldate>
  <nctid>NCT00877006</nctid>
  <trial_identification>
    <studytitle>Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study</studytitle>
    <scientifictitle>An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>C18083/3064/NL/MN</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-Hodgkin's Lymphoma</healthcondition>
    <healthcondition>Mantle Cell Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - bendamustine
Treatment: drugs - rituximab
Treatment: drugs - vincristine
Treatment: drugs - prednisone
Treatment: drugs - cyclophosphamide
Treatment: drugs - doxorubicin

Experimental: Bendamustine and Rituximab (BR) - Participants received the investigational bendamustine and rituximab regimen for 6 to 8 28-day cycles: bendamustine 90 mg/m^2 intravenous (IV) on Days 1 and 2; rituximab 375 mg/m^2 IV on Day 1

Active Comparator: R-CHOP/R-CVP - Participants received the standard regimen (R-CHOP or R-CVP) for 6 to 8 21-days cycles.
R-CHOP: rituximab 375 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; doxorubicin 50 mg/m^2 IV Day 1; cyclophosphamide 750 mg/m^2 IV Day 1; prednisone 100 mg oral on Days 1 to 5
R-CVP: rituximab 375 mg/m^2 IV on Day 1; cyclophosphamide 750 mg/m^2 IV on Day 1 or cyclophosphamide 1000 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; prednisone 100 mg oral on Days 1 to 5


Treatment: drugs: bendamustine


Treatment: drugs: rituximab


Treatment: drugs: vincristine


Treatment: drugs: prednisone


Treatment: drugs: cyclophosphamide


Treatment: drugs: doxorubicin


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants With Complete Response (CR) at End of Treatment Period - CR=complete disappearance of all detectable clinical evidence of disease and disease-related symptoms, if present pretherapy; protocol-specified positron emission tomography (PET) scan assessment criteria; (if the spleen and/or liver were enlarged on the basis of physical examination and/or anatomic imaging before treatment) the liver and/or spleen were considered normal size on physical examination and by anatomic imaging after therapy, with disappearance of all nodules related to lymphoma; (if the bone marrow was involved by lymphoma before treatment) the infiltrate must have cleared on subsequent bone marrow biopsies.</outcome>
      <timepoint>6 to 8 21 or 28-day cycles (18-32 weeks)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Overall Response at End of Treatment Period - Overall Response=participants with Complete Remission (CR) + those with Partial Remission (PR). CR=see Outcome Measure 1 for details. PR= at least a 50% decrease in the sum of the product of the greatest diameters (SPD) of up to 6 of the largest dominant nodes/masses; at least a 50% decrease in the SPD of hepatic and splenic nodules in their greatest transverse diameter; no increase in the size of the liver, spleen, and other nodes; no measurable disease in organs other than the liver or spleen; no new sites of disease; protocol-specified PET scan and bone marrow criteria.</outcome>
      <timepoint>6 to 8 21 or 28-day cycles (18-32 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs at End of Treatment Period - AE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. An AE can, therefore, be any unfavorable and unintended physical sign, symptom, or laboratory parameter that develops or worsens in severity during the course of the study, or significant worsening of the disease under study (or any concurrent disease), whether or not considered related to the study drug. AEs were graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). SAE=an adverse event occurring at any dose that results in: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity (a substantial disruption of one's ability to conduct normal life functions), a congenital anomaly/birth defect, or other important medical event.</outcome>
      <timepoint>32 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Worst Overall Common Terminology Criteria for Adverse Events (CTCAE) Grades for Serum Chemistry Laboratory Test Results - Clinical laboratory data were graded according to National Cancer Institute's (NCI) CTCAE version 3, and graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). The table presents the worst CTCAE grades for serum chemistry test results experienced by participants overall (i.e., the worst post-baseline grade value for each participant and laboratory test across all cycles).</outcome>
      <timepoint>32 weeks (conducted at screening, Day 1 of each cycle, and end-of-treatment visit)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Worst Overall CTCAE Grade for Hematology Laboratory Test Results - Hematology test data were graded according to National Cancer Institute's (NCI) CTCAE version 3, and graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). The table presents the worst CTCAE grades for hematology test results experienced by participants overall (i.e., the worst post-baseline grade value for each participant and hematology test across all cycles).</outcome>
      <timepoint>32 weeks (conducted at screening, Day 1 of each cycle, weekly during treatment, and at the end-of-treatment visit)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically Significant Abnormal Vital Signs</outcome>
      <timepoint>32 weeks (conducted at screening, Day 1 of each cycle, and end-of-treatment visit)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Potentially Clinically Significant Abnormal Weight - Participants were weighed at Baseline and at Endpoint (Week 32); those participants with an increase or decrease of &gt;=10% were considered potentially clinically significant.</outcome>
      <timepoint>Baseline, Week 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Eastern Cooperative Oncology Group (ECOG) Performance Status at the End of Treatment Period - Participants' ECOG Performance Status was evaluated at the end of treatment as improved, stayed the same, or worsened from baseline (see Baseline Characteristics for ECOG Performance Status).</outcome>
      <timepoint>Week 32</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Therapeutic Classification of Prior Medications</outcome>
      <timepoint>prior to start of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Therapeutic Classification of Concomitant Medications</outcome>
      <timepoint>32 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline to End of Treatment in the Global Health Status Score of the European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30) - EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). This outcome reports the global health status on a scale of 0-100 with a high score for the global health status/QOL represents a high quality of life.</outcome>
      <timepoint>Day 1 (prior to treatment), 32 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free Survival and Event-free Survival at End of Follow-up</outcome>
      <timepoint>286 weeks (5.5 years)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival at End of Follow-up</outcome>
      <timepoint>286 weeks (5.5 years)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Median Duration of Response at End of Follow-up</outcome>
      <timepoint>286 weeks (5.5 years)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Histopathologic confirmation of one of the following cluster of differentiation
             antigen 20 positive (CD20+) B-cell non-Hodgkin's lymphomas (tissue diagnostic
             procedures must be performed within 6 months of study entry and with biopsy material
             available for review):

               -  follicular lymphoma (NCI CTCAE grade 1 or 2)

               -  immunoplasmacytoma/immunocytoma (Waldenstrom's macroglobulinemia)

               -  splenic marginal zone B-cell lymphoma

               -  extra-nodal marginal zone lymphoma of mucosa-associated lymphoid tumor (MALT)
                  type

               -  nodal marginal zone B-cell lymphoma

               -  mantle cell lymphoma

          -  Meets one of the following need-for-treatment criteria (with the exception of mantle
             cell lymphoma for which treatment is indicated):

               -  presence of at least one of the following B-symptoms:

                    1. fever (&gt;38ÂºC) of unclear etiology

                    2. night sweats

                    3. weight loss of greater than 10% within the prior 6 months

               -  large tumor mass (bulky disease)

               -  presence of lymphoma-related complications, including narrowing of ureters or
                  bile ducts, tumor-related compression of a vital organ, lymphoma-induced pain,
                  cytopenias related to lymphoma/leukemia, splenomegaly, pleural effusions, or
                  ascites

               -  hyperviscosity syndrome due to monoclonal gammopathy

          -  CD20+ B cells in lymph node biopsy or other lymphoma pathology specimen.

          -  No prior treatment (patients on "watch and wait" may enter the study if a recent
             biopsy [obtained within the last 6 months] is available)

          -  Adequate hematologic function (unless abnormalities related to lymphoma infiltration
             of the bone marrow or hypersplenism due to lymphoma) as follows:

               -  hemoglobin of &gt;= 10.0 g/dL

               -  absolute neutrophil count (ANC) &gt;=1.5*10^9/L

               -  platelet count &gt;=100*10^9/L

          -  Bidimensionally measurable disease (field not previously radiated)

          -  Able to provide written informed consent

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status &lt;=2

          -  Estimated life expectancy &gt;=6 months

          -  Serum creatinine of &lt;=2.0 mg/dL or creatinine clearance &gt;=50 mL/min

          -  Alanine aminotransferase (ALT) and aspartate transaminase (AST) =2.5*upper limit of
             normal (ULN), and alkaline phosphatase and total bilirubin within normal limits

          -  Left ventricular ejection fraction (LVEF) &gt;= 50% by multiple gated acquisition scan
             (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with
             R-CHOP

          -  A medically accepted method of contraception to be used by women of childbearing
             potential (not surgically sterile or at least 12 months naturally postmenopausal)

          -  Men capable of producing offspring and not surgically sterile must practice abstinence
             or use a barrier method of birth control.

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Chronic lymphocytic leukemia, small lymphocytic lymphoma (SLL), or grade 3 follicular
             lymphoma

          -  Transformed disease (bone marrow blasts are permitted; however, transformed disease
             indicating leukemic involvement is not permitted)

          -  Central nervous system (CNS) lymphomatous involvement or leptomeningeal lymphoma

          -  Prior radiation for NHL, except for a single course of locally delimited radiation
             therapy with a radiation field not exceeding 2 adjacent lymph node regions

          -  Active malignancy, other than NHL, within the past 3 years except for localized
             prostate cancer treated with hormone therapy, cervical carcinoma in situ, breast
             cancer in situ, or non-melanoma skin cancer following definitive treatment

          -  New York Heart Association (NYHA) Class III or IV heart failure, arrhythmias or
             unstable angina, electrocardiograph (ECG) evidence of active ischemia or active
             conduction system abnormalities, or myocardial infarction within the last 6 months
             (prior to study entry, ECG abnormalities at screening must be documented by the
             investigator as not medically relevant)

          -  Known human immunodeficiency virus (HIV) positivity

          -  Active hepatitis B or hepatitis C infection (hepatitis B surface antigen testing
             required)

          -  Women who are pregnant or lactating

          -  Corticosteroids for treatment of lymphoma within 28 days of study entry Chronically
             administered low-dose corticosteroids (e.g., prednisone =20 mg/day) for indications
             other than lymphoma or lymphoma-related complications are permitted

          -  Any serious uncontrolled, medical or psychological disorder that would impair the
             ability of the patient to receive therapy

          -  Any condition which places the patient at unacceptable risk or confounds the ability
             of the investigators to interpret study data

          -  Any other investigational agent within 28 days of study entry

          -  Known hypersensitivity to bendamustine, mannitol, or other study-related drugs

          -  Ann Arbor stage I disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>30/04/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>447</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/03/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Teva Investigational Site 315 - Perth</hospital>
    <hospital>Teva Investigational Site 305 - Concord</hospital>
    <hospital>Teva Investigational Site 317 - Douglas</hospital>
    <hospital>Teva Investigational Site 308 - East Melbourne</hospital>
    <hospital>Teva Investigational Site 310 - Fitzroy</hospital>
    <hospital>Teva Investigational Site 311 - Fitzroy</hospital>
    <hospital>Teva Investigational Site 301 - Garran</hospital>
    <hospital>Teva Investigational Site 316 - Geelong</hospital>
    <hospital>Teva Investigational Site 304 - Hobart</hospital>
    <hospital>Teva Investigational Site 312 - Kurralta Park</hospital>
    <hospital>Teva Investigational Site 307 - Melbourne</hospital>
    <hospital>Teva Investigational Site 306 - North Terrace</hospital>
    <hospital>Teva Investigational Site 318 - Parkville</hospital>
    <hospital>Teva Investigational Site 300 - South Brisbane</hospital>
    <hospital>Teva Investigational Site 303 - Westmead</hospital>
    <hospital>Teva Investigational Site 314 - Wodonga</hospital>
    <hospital>Teva Investigational Site 313 - Woodville</hospital>
    <hospital>Teva Investigational Site 309 - Woolloongabba</hospital>
    <postcode> - Perth</postcode>
    <postcode> - Concord</postcode>
    <postcode> - Douglas</postcode>
    <postcode> - East Melbourne</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode> - Garran</postcode>
    <postcode> - Geelong</postcode>
    <postcode> - Hobart</postcode>
    <postcode> - Kurralta Park</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - North Terrace</postcode>
    <postcode> - Parkville</postcode>
    <postcode> - South Brisbane</postcode>
    <postcode> - Westmead</postcode>
    <postcode> - Wodonga</postcode>
    <postcode> - Woodville</postcode>
    <postcode> - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Barretos-SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Brasilia, DF</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Curitiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Goiania-GO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Jau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Lajeado-RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro - RJ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Santo Andre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Barrie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Halifax</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ottawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vancouver</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Winnipeg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Aguascalientes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Hermosillo, Sonora</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey - NL</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Newtown</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Palmerston North</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Takapuna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Miraflores</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Teva Branded Pharmaceutical Products, R&amp;D Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of the study is to compare the complete response (CR) rate of
      bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab,
      cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide,
      doxorubicin, vincristine, and prednisone (R-CHOP) in patients with advanced, indolent
      non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00877006</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sponsor's Medical Expert</name>
      <address>Cephalon</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>